Chardan analyst Daniil Gataulin downgraded Clearside Biomedical (CLSD) to Neutral from Buy without a price target after the company said it will explore strategic alternatives. The firm awaits clarity on Clearside’s future plans.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties
- Needham downgrades Clearside on ‘disappointing’ decision to explore options
- Clearside Biomedical downgraded to Hold from Buy at Needham
- Clearside Biomedical downgraded to Hold from Buy at JonesResearch